Tailored pharmacotherapy monitoring in Parkinson's disease and Schizophrenia using a rapid and sensitive α-Synuclein assay.

Journal: Clinica chimica acta; international journal of clinical chemistry
Published Date: May 6, 2025

Abstract

BACKGROUND: While Parkinson's disease is a low dopamine neurodegenerative disorder, Schizophrenia is considered a high dopamine psychiatric disorder. Pharmacological interventions that are directed to normalize dopamine concentrations in the mid-brain for an extended duration lead to unintended consequences. Parkinson's disease patients experience psychosis, and Schizophrenia patients develop extra-pyramidal symptoms due to dopamine levels overshooting their physiological range. An objective monitoring technique is therefore required for better therapeutic efficacy in these two neurological diseases.

Authors

  • Neelam Upadhyay
    Department of Biophysics, All India Institute of Medical Sciences New Delhi, 110023, India.
  • Manjari Tripathi
    Department of Neurology, All India Institute of Medical Sciences New Delhi, 110023, India.
  • Rakesh Kumar Chaddha
    Department of Psychiatry, All India Institute of Medical Sciences New Delhi, 110023, India.
  • Rashmi Ramachandran
    Department of Anesthesia, All India Institute of Medical Sciences New Delhi, 110023, India.
  • Arunmozhimaran Elavarasi
    Department of Neurology, All India Institute of Medical Sciences New Delhi, 110023, India.
  • Gururao Hariprasad
    Department of Biophysics, All India Institute of Medical Sciences New Delhi, 110023, India. Electronic address: dr.hariprasadg@gmail.com.
  • Ravikrishnan Elangovan
    Department of Biochemical Engineering & Biotechnology, Indian Institute of Technology New Delhi, 110052, India. Electronic address: elangovan@dbeb.iitd.ac.in.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals